Drugs / GSK618334
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01036061 | Sep 2009 → Feb 2010 | substance dependence | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00814957 | Dec 2008 → Jun 2009 | substance dependence | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00513279 | Jun → Oct 2007 | substance dependence | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK618334 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00513279 ↗ |
| Action | Inhibit | “D3 receptor antagonist” NCT00814957 ↗ |
| Route | Oral | “GSK618334 will be swallowed with 250 milliliters (mL) of water.” NCT00513279 ↗ |